-

12:35:07 PM

BWV Stock News

BWV - Blue Water Vaccines Inc

05/19/22 2:00 PM

Nasdaq : BWV

low float

Blue Water Vaccines Announces Collaboration with Instituto Butantan for the Development of BWV-101, a Universal Influenza Vaccine Candidate

Blue Water Vaccines, Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a biopharmaceutical company developing vaccines, announces a collaboration with the multidisciplinary Center for R&D in Immunobiologics (“CeRDI”), an initiative of Instituto

RHEA-AI

very positive

05/13/22 5:01 PM

Nasdaq : BWV

earningslow float

Blue Water Vaccines Reports First Quarter 2022 Financial Results and Recent Business Developments

Closed initial public offering of 2,222,222 shares of common stock at a public offering price of $9.00 per share, with aggregate gross proceeds of approximately $20 million Multiple vaccine candidate developments, including additional data for universal influenza candidate, BWV-101, identifying

RHEA-AI

neutral

05/12/22 8:30 AM

Nasdaq : BWV

conferenceslow float

Blue Water Vaccines Inc. to Present at H.C. Wainwright Global Investment Conference

Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced that Erin Henderson, Chief Business Officer of

RHEA-AI

neutral

05/11/22 1:00 PM

Nasdaq : BWV

low float

Blue Water Vaccines Announces Expanded License Agreement with St. Jude Children’s Research Hospital for Novel Bacterial Vaccine Platform

Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing transformational vaccines, today announced an expanded license agreement has been signed with St. Jude Children’s Research Hospital (“St.

RHEA-AI

neutral

04/21/22 8:45 AM

Nasdaq : BWV

low float

Blue Water Vaccines Presents New Data Supporting Universal Influenza Vaccine Candidate at the World Vaccine Congress 2022 in Washington, DC

Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing transformational vaccines, today issued the below statement regarding its Form 8-K filed with the Securities and Exchange Commission

RHEA-AI

neutral

04/20/22 9:25 AM

Nasdaq : BWV

low float

Blue Water Vaccines Announces Closing of $8 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant global

RHEA-AI

neutral

04/18/22 7:30 AM

AMEX, Nasdaq : OGEN, BWV, CRXT

conferences

Oragenics to Participate at the World Vaccine Congress Washington 2022

Oragenics, Inc., a biotech company dedicated to fighting infectious diseases including coronavirus, today announced that Kimberly Murphy, a member of the Company’ s Board of Directors, will attend the upcoming World Vaccine Congress Washington that will be held on April 18-22 to showcase the Company’ s lead product, NT-CoV2-1, an intranasal vaccine candidate,...

RHEA-AI

neutral

04/13/22 9:30 AM

Nasdaq : BWV

low float

Blue Water Vaccines Announces $8 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing transformational vaccines to address significant global

RHEA-AI

neutral

04/11/22 9:56 AM

Nasdaq : BWV

conferenceslow float

Blue Water Vaccines Inc to Present at World Vaccine Congress Washington 2022

Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a

RHEA-AI

neutral

03/22/22 7:00 AM

Nasdaq : BWV

low float

Blue Water Vaccines Announces Publication in Nano Research Supporting Novel S&P Vaccine Platform Versatility

Blue Water Vaccines has exclusive, global licensing rights to Cincinnati Children’s Hospital Medical Center’s novel virus-like particle (VLP) vaccine platform. The data supports BWV’s ongoing development of a transformational universal influenza vaccine, as well as a rotavirus & norovirus vaccine

RHEA-AI

neutral